S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Jury gets chance to hear Elizabeth Holmes' bold promises

Friday, October 22, 2021 | Michael Liedtke, AP Technology Writer

In this Tuesday, Aug. 31, 2021, file photo, Elizabeth Holmes, founder and CEO of Theranos, arrives at the federal courthouse for jury selection in her trial, in San Jose, Calif. A jury weighing the fate of fallen Silicon Valley star Holmes got its first chance Friday, Oct. 22, to listen to recordings of her boasting to investors about purported breakthroughs in a blood-testing technology. (AP Photo/Nic Coury, File)

SAN JOSE, Calif. (AP) — A jury weighing the fate of fallen Silicon Valley star Elizabeth Holmes got its first chance Friday to listen to recordings of her boasting to investors about purported breakthroughs in a blood-testing technology.

The technology heralded as a quantum leap in blood testing, however, later dissolved into a scandal that now threatens to send her to prison.

The drama unfolded in a San Jose, California, courtroom with federal prosecutors playing a series of recordings from a December 2013 conference call that Holmes held with investors in Theranos, the company she started in 2003 after dropping out of college at 19 in hopes of becoming a revered visionary in the mold of Apple co-founder Steve Jobs.

The audio clips of Holmes capped the sixth week of a high-profile trial revolving around allegations that Holmes duped sophisticated investors and major retailers with bogus promises about a Theranos device dubbed Edison. The company's machine was supposed to be able to quickly scan for hundreds of potential health problems with a few drops of blood taken with a finger prick.

In the recordings, Holmes — speaking in a husky voice that some critics said she adopted to sound more authoritative — boasted about partnerships with big pharmaceutical companies such as Pfizer that evidence in the trial has revealed didn't pan out. She also mentioned contracts that never materialized because Theranos couldn't get the Edison to work properly. The device's repeated failures disillusioned former U.S. Defense Secretary James Mattis, a former Theranos board member ally who testified earlier in the trial.

“We could establish what has the opportunity to be the largest lab in the country,” Holmes told investors in one of the clips played Friday. She laid out that ambition just a few months after Theranos had struck a deal to set up blood-testing “wellness centers" in Walgreens stores across the country.

But Theranos wound up in only 40 Walgreens stores. After investing $140 million in Theranos, Walgreens wound up ending the Theranos alliance in 2016, not long after a series of explosive articles in The Wall Street Journal and regulatory audits exposed chronic flaws in the blood-testing technology.

Before everything blew up, Holmes raised hundreds of millions of dollars from a list of investors that included billionaires such as media mogul Rupert Murdoch, the Walton family behind Walmart, and Oracle co-founder Larry Ellison. The clips played Friday were recorded by Bryan Tolbert, an adviser to Dallas real estate developer Carl Hall, who invested $7 million in Theranos.

The flurry of investments at one point valued privately held Theranos at $9 billion, including a $4.5 billion stake owned by Holmes. Now she is facing up to 20 years in prison if she is convicted in a trial that is scheduled to continue until late this year.

As she has done throughout the trial, Holmes on Friday sat stoically alongside her lawyers while her voice filled the courtroom. She has yet to have a reason to speak during the trial, though her attorneys have signaled she make eventually take the witness stand to defend her actions as Theranos' CEO.

Holmes, 37, has denied any wrongdoing, and blamed any misconduct on her former boyfriend, Ramesh “Sunny" Bulwani, who was Theranos' chief operating officer. In court documents, Holmes' lawyers have asserted she was manipulated by Bulwani, a charge his lawyer has vehemently denied. Bulwani faces a separate trial next year.

The jury that listened raptly to the recordings of Holmes was whittled down Friday when U.S. District Judge Edward Davila dismissed one member for an undisclosed reason. Originally composed of 17 people, including five alternates, the jury is now down to 10 men and four women.

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)2.9$53.73+2.5%2.90%15.99Hold$50.53
Compare These Stocks  Add These Stocks to My Watchlist 


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.